Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial.

Wong AW, Chan SS, Yeo W, Yu MY, Tam WH.

Obstet Gynecol. 2013 May;121(5):943-50. doi: 10.1097/AOG.0b013e31828bf80c. Erratum in: Obstet Gynecol. 2013 Sep;122(3):698.

PMID:
23635729
2.

A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women.

Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, Kwan WH, Yuen PM.

BJOG. 2007 Dec;114(12):1510-5.

3.

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.

Dominick S, Hickey M, Chin J, Su HI.

Cochrane Database Syst Rev. 2015 Dec 9;(12):CD007245. doi: 10.1002/14651858.CD007245.pub3. Review.

PMID:
26649916
4.

Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.

Chin J, Konje JC, Hickey M.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007245. doi: 10.1002/14651858.CD007245.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;12:CD007245.

PMID:
19821400
5.

Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen.

Kesim MD, Aydin Y, Atis A, Mandiraci G.

Climacteric. 2008 Jun;11(3):252-7. doi: 10.1080/13697130802163168.

PMID:
18568790
6.

Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.

Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, Bell SC, Taylor DJ.

Lancet. 2000 Nov 18;356(9243):1711-7.

PMID:
11095258
7.
8.

The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.

Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Cuzick J, Coibion M, Bianco AR.

BJOG. 2003 Dec;110(12):1099-106.

9.

Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.

Ewies AA, Alfhaily F.

Obstet Gynecol Surv. 2012 Nov;67(11):726-33. doi: 10.1097/OGX.0b013e318273570b. Review.

PMID:
23151756
10.

Indication of hysteroscopy in tamoxifen treated breast cancer patients.

Taponeco F, Curcio C, Fasciani A, Giuntini A, Artini PG, Fornaciari G, Petraglia F, Genazzani AR.

J Exp Clin Cancer Res. 2002 Mar;21(1):37-43.

PMID:
12071527
11.

Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.

Gallos ID, Ganesan R, Gupta JK.

Obstet Gynecol. 2013 Jun;121(6):1165-71. doi: 10.1097/AOG.0b013e31828cb563.

PMID:
23812448
12.

Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.

Fu Y, Zhuang Z.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6419-29. eCollection 2014. Review.

13.

Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.

Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P, Zullo F.

Gynecol Endocrinol. 2013 Feb;29(2):156-9. doi: 10.3109/09513590.2012.730579. Epub 2012 Nov 7.

PMID:
23134558
14.

Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding.

Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O.

Obstet Gynecol. 1997 Aug;90(2):257-63.

PMID:
9241305
15.

Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial.

Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M.

Gynecol Oncol. 2009 Sep;114(3):452-6. doi: 10.1016/j.ygyno.2009.06.014. Epub 2009 Jul 3.

PMID:
19576623
16.

[Tamoxifen, endometrial cancer and levonorgestrel intra-uterine device].

Espié M.

Gynecol Obstet Fertil. 2003 Oct;31(10):867-71. French.

PMID:
14642946
17.

Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland.

Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E.

Obstet Gynecol. 2014 Aug;124(2 Pt 1):292-9. doi: 10.1097/AOG.0000000000000356.

PMID:
25004338
18.

[Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].

Boutet G.

Gynecol Obstet Fertil. 2006 Nov;34(11):1015-23. Epub 2006 Nov 7. Review. French.

PMID:
17092752
19.
20.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N.

J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.

PMID:
9747868

Supplemental Content

Support Center